[Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment].

Takako Tsumura(Hiroshima University), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Koji Waki(Frontier Science Foundation), Akira Hiramatsu(Hiroshima University), Michio Imamura(Hiroshima University), Masataka Tsuge(Hiroshima University), Tomokazu Kawaoka(Hiroshima University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Hiromi Sanetou, Shoichi Takahashi(Hiroshima University), Takahiro Azakami, Yoshio Katamura(Hiroshima University), Shintaro Takaki(Frontier Science Foundation), Koji Arihiro(Hiroshima University Hospital), Yoshiiku Kawakami(Hiroshima University Hospital), Yuki Kimura(Jichi Medical University)
PubMed
May 1, 2009
Cited by 5

Related Papers

Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells
|Cell stem cell|2010|670
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599